Physician

Alex Reyentovich, M.D.

According to 2025 Medicare claims, Alex Reyentovich, M.D. (NPI: 1588723662) practices advanced heart failure and transplant cardiology in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from New York, NY. This provider's primary affiliated billing organization is NEW YORK UNIVERSITY (NPI: 1285826438; TIN: 472665045) and primary practice location at 10016-6402.

Reyentovich's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 358 traditional Medicare patients, billed 1,214 HCPCS/CPT codes, and received $120,854 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 615 prescription claims across 144 beneficiaries totaling $176,209 in drug costs, led by Jardiance (Empagliflozin). DME data shows 43 claims. Open Payments data shows 30 records totaling $5,235. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved from a higher plateau to a lower plateau, from $281,395 to $176,209. In contrast, DME billing represents a smaller volume and rose steadily, from $3,415 to $5,977.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	304	1,535	$116,449
2016	349	1,671	$124,084
2017	329	1,603	$118,577
2018	336	1,355	$104,105
2019	401	1,539	$135,957
2020	385	1,327	$114,865
2021	405	1,402	$144,748
2022	349	1,320	$131,384
2023	363	1,234	$124,203
2024	358	1,214	$120,854

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	173	1,906	$281,395
2016	203	1,387	$254,360
2017	202	1,482	$430,911
2018	207	1,507	$416,587
2019	199	1,270	$233,721
2020	166	1,068	$309,962
2021	163	737	$174,386
2022	136	552	$138,579
2023	146	525	$150,910
2024	144	615	$176,209

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	84	$184,516
2016	N/R	29	$145,921
2017	N/R	39	$154,265
2018	N/R	130	$125,309
2019	N/R	184	$15,553
2020	N/R	170	$9,731
2021	N/R	352	$19,920
2022	N/R	394	$39,084
2023	N/R	359	$43,266
2024	N/R	43	$5,313

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	36	36	$188
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	271	450	$152
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	41	124	$102
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	19	40	$69
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	171	254	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jardiance	Empagliflozin	41	2,790	$54,712
Entresto	Sacubitril/Valsartan	28	1,920	$40,222
Eliquis	Apixaban	33	1,890	$35,504
Eplerenone	Eplerenone	46	3,510	$2,785
Metoprolol Succinate	Metoprolol Succinate	61	4,694	$1,179

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4222	Infusion supplies for external drug infusion pump, per cassette or bag (list drugs separately)	N	N/R	16	$3,746
J2260	Injection, milrinone lactate, 5 mg	N	N/R	16	$1,356
A4221	Supplies for maintenance of non-insulin drug infusion catheter, per week (list drugs separately)	N	N/R	11	$211

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	30	$5,235	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alex Reyentovich, M.D.?

Tedicare shows public-source Medicare data for Alex Reyentovich, M.D. (NPI 1588723662), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alex Reyentovich, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alex Reyentovich, M.D.?

Alex Reyentovich, M.D. is linked to NEW YORK UNIVERSITY (billing NPI 1285826438) in the available physician profile data.

Does Alex Reyentovich, M.D. have Open Payments data?

Alex Reyentovich, M.D. has 30 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.